Abstracts tagged "autoimmune diseases"

Abstract Number: 2580 • ACR Convergence 2025
Estrogen Modulates Neutrophil Biology: Implications for Autoimmunity
William Ambler¹, Eduardo Patino-Martinez¹, Gustaf Wigerblad¹, Shuichiro Nakabo², Jorge Romo-Tena³, Norio Hanata⁴, James Simone¹, Stephen Brooks¹, Kan Jiang⁵, Hong-wei Sun¹, Faiza Naz⁶, Shamima Islam⁶, Gustavo Gutierrez-Cruz¹, Stefania Dell'Orso¹, Anshu Deewan⁷, Vicky Chen⁷, Paul Schaughency⁸, Carmelo Carmona-Rivera⁴, Sarfaraz Hasni¹, Veronica Gomez-Lobo⁹ and Mariana Kaplan⁴, ¹NIH/NIAMS, Bethesda, MD, ²NIAMS, NIH, Bethesda, MD, ³Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ⁴Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, Bethesda, MD, ⁵Biodata Mining and Discovery Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, Bethesda, ⁶National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ⁷NIH/NIAID, Bethesda, MD, ⁸NIAID, NIH, Bethesda, MD, ⁹NIH/NICHD, Bethesda, MD
Background/Purpose: Neutrophils are essential for inflammation and host defense against infections. Our group has previously highlighted their key roles in the pathogenesis of diseases that…
Abstract Number: 2463 • ACR Convergence 2025
Allogenic anti- CD19 CAR-T cells induce remission in refractory systemic lupus erythematosus
Chunnei Yang¹, Chuanyin Sun², Binghe Tan³, Chao Hu¹, Liyan Wan², Changling Xie³, Qian Tan³, Mingyao Liu³, Jin Lin², Bing Du³ and Hongyan Tong¹, ¹Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China (People's Republic), ²Department of Rheumatology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China (People's Republic), ³BRL Medicine Inc., Shanghai, Shanghai, China (People's Republic)
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease associated with significant morbidity and mortality. The treatment approach for SLE primarily involves immunomodulation and…
Abstract Number: 2292 • ACR Convergence 2025
Safety and Humoral Response to Recombinant Herpes Zoster Vaccine in immunosuppressed Sjögren’s Disease Patients: Results From a Double-Blinded Placebo-Controlled Study
Sandra G Pasoto¹, Talita Ribeiro², Nadia Emi Aikawa³, Ana C Medeiros-Ribeiro¹, Bruno Borges², Andre Franco⁴, Henrique Silva², Eloisa Bonfa⁵ and Clovis Artur Silva⁶, ¹Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, Brazil, ²Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, Brazil, ³Rheumatology Division and Pediatric Rheumatology Unit, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, São Paulo, Brazil, ⁴Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, Sao Paulo, Brazil, ⁵Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, São Paulo, Brazil, ⁶University of São Paulo, São Paulo, São Paulo, Brazil
Background/Purpose: Immunosuppressed Sjögren’s disease (SjD) patients are at increased risk of herpes zoster (HZ). Despite this vulnerability, data on safety and immunogenicity of the recombinant…
Abstract Number: 1979 • ACR Convergence 2025
Utility of ALT/AST and Fibrosis-4 Index (FIB-4) Score in Monitoring Methotrexate Hepatotoxicity in Rheumatologic Disease: A Retrospective Analysis
Julia Wajsberg¹, Dana Nachawati², Lenche Kostadinova³, Donald Anthony⁴ and Maya Mattar³, ¹University Hospitals Cleveland Medical Center/Case Western Reserve University, Cleveland, OH, ²University Hospitals, Cleveland, ³Louis Stolkes Cleveland VA, Cleveland, ⁴The MetroHealth System at Case Western Reserve University School of Medicine, Cleveland, OH
Background/Purpose: Methotrexate (MTX) is widely used in rheumatologic disease but carries hepatotoxic risk. Standard monitoring relies on measurement of alanine and aspartate aminotransferase (ALT and…
Abstract Number: 1778 • ACR Convergence 2025
Towards an Earlier and Accurate Diagnosis of Connective Tissue Disease-related Interstitial Lung Disease: TGFB Isoform Genes as Upcoming Biomarkers
Verónica Pulito Cueto¹, Joao Carlos Batista-Liz¹, Rebeca Nieto-Nieto², Clara Vaquera-Illescas², Diego San Emeterio-Villar², Daniel Vicente-Mínguez², María Sebastián Mora-Gil², Belén Atienza-mateo³, Ana Serrano-Combarro⁴, David Iturbe-Fernández⁵, Victor M. Mora-Cuesta⁵, Carolina Aguirre-Portilla⁴, Jose M Cifrián⁵, Ricardo Blanco⁴ and Raquel Lopez Mejias¹, ¹IDIVAL, Santander, Spain, ²Immunopathology Group, IDIVAL, Santander, Spain, ³Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, PALMA DE MALLORCA/BALEARES, Spain, ⁴Immunopathology Group, IDIVAL and Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁵Immunopathology Group, IDIVAL and Division of Pneumology, Hospital Universitario Marqués de Valdecilla, Santander, Spain
Background/Purpose: Interstitial lung disease (ILD) is one of the leading cause of mortality in patients with connective tissue diseases (CTDs) [1]. The onset of CTD-ILD…
Abstract Number: 1662 • ACR Convergence 2025
Efficacy and Safety of Nerandomilast in Patients with Autoimmune Disease-Related Progressive Pulmonary Fibrosis: Subgroup Analysis of the FIBRONEER-ILD trial
Anna-Maria Hoffmann-Vold¹, Shervin Assassi², Vincent Cottin³, Michael Kreuter⁴, Claudia Valenzuela⁵, Marlies S Wijsenbeek⁶, Hui Gu⁷, Ivana Ritter⁸, Susanne Stowasser⁸, Gerrit Weimann⁸ and Toby M Maher⁹, ¹Oslo University Hospital, Oslo, Norway, ²Division of Rheumatology, UTHealth Houston, Houston, Texas, USA, Houston, TX, ³National Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, Hospices Civils de Lyon, Claude Bernard University Lyon ¹, UMR ⁷⁵⁴, ERN-LUNG, Lyon, France, Lyon, France, ⁴Center for Pulmonary Medicine, Department of Pneumology, Mainz University Medical Center and Pulmonary, Critical Care & Sleep Medicine, Marienhaus Clinic Mainz, Mainz, Germany, Heidelberg, Germany, ⁵Pulmonology Department, Hospital Universitario de la Princesa, Universidad Autónoma de Madrid, Madrid, Spain, Madrid, Spain, ⁶Center of Expertise for Interstitial Lung Diseases, Department of Respiratory Medicine, Erasmus MC, University Medical Centre, Rotterdam, The Netherlands, Rotterdam, Netherlands, ⁷Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA, Ridgefield, ⁸Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ⁹Department of Pulmonary, Critical Care and Sleep Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA and Section of Inflammation, Repair and Development, National Heart and Lung Institute, Imperial College London, London, UK, Los Angeles
Background/Purpose: Nerandomilast is a preferential inhibitor of phosphodiesterase 4B with antifibrotic and immunomodulatory properties. The Phase III FIBRONEER-ILD trial in patients with progressive pulmonary fibrosis…
Abstract Number: 1502 • ACR Convergence 2025
Prevalence and Associated Factors of Autoimmune Hepatitis and Primary Sclerosing Cholangitis in Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis
Bisma Shaikh¹, Sarfaraz Hasni² and Omer Pamuk³, ¹Jinnah Sindh Medical University, Karachi, Pakistan, ²NIH/NIAMS, Bethesda, MD, ³University Hospitals Cleveland Medical Center/ Case Western Reserve University, Cleveland, OH
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune, chronic disorder characterized by multi-system organ involvement. The hepatic involvement in SLE is categorized as a primary…
Abstract Number: 1362 • ACR Convergence 2025
Multimodal Spatial and Single-Cell Profiling of Synovial Tissue Reveals Macrophage Programs Associated with Biologic TherapyTreatment Response in Rheumatoid Arthritis
Mohammad Daud Khan¹, Matthew Dapas², Salina T Dominguez¹, Tyler Therron³, Kathleen Aren⁴, Mary Carns⁵, Hadijat Makinde⁵, Arthur M Mandelin¹, Eric M Ruderman¹, John F Seagrist⁵, Ruth Misha¹, Carla Marie Cuda⁵, Harris R Perlman⁵ and Deborah Rachelle Winter⁶, ¹Northwestern University, Chicago, ²Northwestern University Feinberg School of Medicine, Chicago, IL, ³Northwestern Feinberg School of Medicine, Chicago, IL, ⁴Northwestern University Division of Rheumatology, Chicago, IL, ⁵Northwestern University, Chicago, IL, ⁶Northwestern University, Skokie, IL
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease driven by persistent synovial inflammation and progressive joint damage. Selecting an effective biologic therapy remains a…
Abstract Number: 1174 • ACR Convergence 2025
High Prevalence of Autoimmunity in Rosai Dorfman Disease: A Multinational Study
Mitali Sen¹, Gordon Ruan², Samuel Reynolds³, Haadi Ali³, Xi Yang³, Diana Morlote¹, Aishwarya Ravindran¹, Lauren Shea¹, Matthew Koster⁴, Jithma Abeykoon², Hind Salama⁵, Xin-Xin Cao⁶, Asra Ahmed³, Ronald Go² and Gaurav Goyal¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²Mayo Clinic, Rochester, ³University of Michigan, Michigan, ⁴Mayo Clinic, Rochester, MN, ⁵National Guard Health Affairs, Riyadh, Saudi Arabia, ⁶Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China (People's Republic)
Background/Purpose: Rosai-Dorfman Disease (RDD), formerly known as sinus histiocytosis with massive lymphadenopathy, was initially thought to be inflammatory or autoimmune in nature. The discovery of…
Abstract Number: 1071 • ACR Convergence 2025
Depression and Mental Health Service Gaps in Autoimmune Disease: Insights from a Simulated BRFSS Dataset
Malay Rathod¹, Shivani Modi², Veera Durga Vaishnavi Kurra³, Karan Yagnik⁴ and Doantrnag Du⁴, ¹Monmouth Medical Center, Ewing, NJ, ²Jefferson Einstein Montgomery Hospital, Ewign, NJ, ³University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁴Monmouth Medical Center, Long Branch, NJ
Background/Purpose: Autoimmune diseases are complex conditions that may predispose individuals to an increased mental health burden, including depression. The immune system leads to inflammation in…
Abstract Number: 0960 • ACR Convergence 2025
Pharmaceutical Blockade of the Neonatal Fc Gamma Receptor Ameliorates Autoimmunity, Inflammation and Fibrosis in the Topoisomerase I Mouse Model of Systemic Sclerosis
Cuong Tran-Manh¹, Thuong Trinh-Minh², Christoph Liebel³, Bas van der Woning⁴, Piotr Zabrocki⁵ and Jörg Distler⁶, ¹Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University., Düsseldorf, Nordrhein-Westfalen, Germany, ²Clinic for Rheumatology University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany; Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Nordrhein-Westfalen, Germany, ³Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University., Düsseldorf, Germany, ⁴argenx BV, Boston, MA, ⁵argenx, Ghent, Belgium, ⁶University Hospital Duesseldorf and HHU, Duesseldorf, Germany
Background/Purpose: SSc is a rare, chronic, systemic autoimmune rheumatic disease characterized by progressive skin and internal organ fibrosis, severe vasculopathy and immune dysregulation with production…
Abstract Number: 0909 • ACR Convergence 2025
Loss of MicroRNA29 expression in B cells and skin microbiota synergize to promote atopic dermatitis in mice.
Marcus Hines¹, Timothy Borbet² and Sergei Koralov², ¹New York University Grossman School of Medicine, New York, NY, ²NYU Langone Medical Center, New York
Background/Purpose: The microRNA(miR)29 family is encoded by two separate loci, the miR29ab1 and miR29b2c alleles. We have previously shown that the microRNA(miR)29 family regulates the…
Abstract Number: 0625 • ACR Convergence 2025
DNA methylation patterns in systemic lupus erythematosus associated with nephritis status
Meghan Nelson¹, Mary Horton², Joanne Nititham³, Jinoos Yazdany⁴, Maria Dall'Era⁵, Cristina Lanata³ and Lindsey Criswell², ¹NIH/NIAMS/NHGRI, Bethesda, MD, ²NIH/NHGRI, Bethesda, MD, ³NIH/NHGRI, Bethesda, ⁴UCSF, San Francisco, CA, ⁵Division of Rheumatology, University of California, San Francisco, CA
Background/Purpose: Individuals with systemic lupus erythematosus (SLE) experience significant variability in clinical outcomes. Our current understanding of the causes of disease heterogeneity are limited, preventing…
Abstract Number: 0802 • ACR Convergence 2025
Remission from cutaneous manifestations of lupus with enpatoran, a first-in-class oral small molecule toll-like receptor 7/8 inhibitor: pooled post-hoc exploratory analysis from a randomized placebo-controlled Phase II study
Eric Morand¹, Victoria Werth², Richard Furie³, Sanjeev Roy⁴, Ruth Fernandez Ruiz⁵, Summer Goodson⁶, Hans Gühring⁷, Flavie Moreau⁶ and David Pearson⁸, ¹Centre for Inflammatory Diseases, Monash University and Monash Health, Melbourne, Victoria, Australia, ²University of Pennsylvania, Philadelphia, PA, ³Division of Rheumatology, Northwell Health, Great Neck, NY, ⁴Ares Trading SA, an affiliate of Merck KGaA, Darmstadt, Germany, Eysins, Switzerland, ⁵EMD Serono, Billerica, PA, ⁶EMD Serono, Billerica, MA, ⁷The healthcare business of Merck KGaA, Darmstadt, Germany, ⁸Department of Dermatology, University of Minnesota, Minneapolis, MN
Background/Purpose: Cutaneous manifestations of lupus are highly prevalent and have a significant impact on patients’ physical and mental health and wellbeing; however, no targeted therapy…
Abstract Number: 0361 • ACR Convergence 2025
Transition in Focus: Health Care Utilization and Disease Status in Youth with Connective Tissue Diseases— A Single-Center Experience in British Columbia, Canada
Mercedes Chan¹, Lori Tucker¹, Jude AlMasoud¹, Jaime Guzman², Andrea Human¹, David Cabral³, Angela How⁴, Wendy Wong⁵ and Jennifer Corpuz⁶, ¹BC Children's Hospital, Vancouver, BC, Canada, ²University of British Columbia and BC Children's Hospital, Vancouver, BC, Canada, ³BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada, ⁴UBC, Vancouver, BC, Canada, ⁵University of British Columbia, Surrey, BC, Canada, ⁶UBC, New Westminster, BC, Canada
Background/Purpose: Graduating from child and family-oriented to adult-oriented health care is a vulnerable time when youth with chronic disease drop out of, or disengage from,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].